BofA warns Fed risks policy mistake with early rate cuts
Investing.com - Truist Securities initiated coverage on Disc Medicine (NASDAQ:IRON), a $2 billion market cap biotech company, with a Buy rating and a price target of $86.00 on Monday. The company maintains strong analyst support, with a consensus rating of Strong Buy and price targets ranging from $75 to $132.
The research firm views Disc Medicine as a compelling investment opportunity due to several key value drivers in the company’s hematological disorders pipeline. According to InvestingPro data, the company maintains a GOOD overall financial health score and holds more cash than debt on its balance sheet.
Truist highlighted the company’s lead asset bitopertin for the rare genetic disorder EPP as already de-risked, with significant upside potential for accelerated approval by the second half of 2026 and positive confirmatory data expected by early 2027.
The firm also pointed to DISC-0974 as a potential blockbuster anemia treatment with favorable risk/reward characteristics and substantial upside potential.
Additionally, Truist noted that DISC-3405, being developed for the blood disorder polycythemia vera (PV), is likely to gain increased attention next year, adding "another leg to the story" for the clinical-stage biotech company.
In other recent news, Disc Medicine has announced its plan to submit a New Drug Application (NDA) for bitopertin in October 2025, following positive feedback from a pre-NDA meeting with the U.S. Food and Drug Administration. This submission is set to proceed under the FDA’s accelerated approval pathway, which could potentially make bitopertin the first disease-modifying therapy for erythropoietic protoporphyria (EPP). Additionally, Raymond (NSE:RYMD) James has reiterated a Strong Buy rating for Disc Medicine, maintaining a price target of $89.00. This comes in light of Bristol Myers (NYSE:BMY) Squibb’s recent trial results for luspatercept, which missed its primary endpoint but showed meaningful secondary benefits. In a strategic move, Disc Medicine has appointed Nadim Ahmed to its board of directors, bringing his extensive experience from roles at Cullinan Therapeutics and Bristol Myers Squibb. Morgan Stanley (NYSE:MS) has also initiated coverage on Disc Medicine with an Overweight rating and a price target of $85.00, citing the potential accelerated market entry of bitopertin. The firm projects significant sales for bitopertin and highlights the upside potential of Disc Medicine’s pipeline, including DISC-0974. These developments reflect ongoing strategic and operational progress at Disc Medicine.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.